7.1397

70.40% 2.9497

Bolt Biotherapeutics Inc (BOLT)

Overview News Price History Financials Discussions Forecast Stock Split

Bolt Biotherapeutics Inc stock is traded at $7.1397, with a volume of 8.76M. It is up +70.40% in the last 24 hours and up +95.61% over the past month. Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Previous Close:

$4.19

Open:

$6.98

24h Volume:

8.76M

Relative Volume:

314.15

Market Cap:

$13.75M

Revenue:

$6.50M

Net Income/Loss:

$-29.58M

P/E Ratio:

-0.437

EPS:

-16.3362

Net Cash Flow:

$-34.58M

1W Performance:

+78.49%

1M Performance:

+95.61%

6M Performance:

+49.68%

1Y Performance:

+23.95%

1-Day Range:

$5.99

$7.78

1-Week Range:

$3.9467

$4.4801

52-Week Range:

$3.10

$7.78

Bolt Biotherapeutics Inc Stock (BOLT) Company Profile

Name

Bolt Biotherapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (594)

Phone

650-665-9295

Address

900 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

BOLT's Discussions on Twitter

Compare BOLT vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BOLT Bolt Biotherapeutics Inc	7.1397	13.75M	6.50M	-29.58M	-34.58M	-16.34
VRTX Vertex Pharmaceuticals Inc	525.60	133.22B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.17	82.90B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	202.72	80.93B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	870.01	54.71B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.70	42.39B	5.76B	514.49M	1.10B	4.4813

Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-29-26	Initiated	Rodman & Renshaw	Buy
Oct-20-25	Resumed	H.C. Wainwright	Buy
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-21	Initiated	Guggenheim	Buy
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	SVB Leerink	Outperform
Mar-02-21	Initiated	Stifel	Buy

View All

Bolt Biotherapeutics Inc Stock (BOLT) Latest News

Sep 22, 2026

Bolt Biotherapeutics CEO Quinn sells $58,402 in stock By Investing.com - Investing.com South Africa

Sep 22, 2026

Bolt Biotherapeutics CEO Quinn sells $58,402 in stock - Investing.com India

Sep 22, 2026

Sep 21, 2026

Bolt Biotherapeutics CEO Quinn sells $58,402 in stock - Investing.com

Sep 21, 2026

Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares By Investing.com - Investing.com India

Sep 21, 2026

Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares By Investing.com - Investing.com Nigeria

Sep 21, 2026

Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares By Investing.com - Investing.com Canada

Sep 21, 2026

Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares - Investing.com

Sep 21, 2026

Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares - Investing.com

Sep 21, 2026

Bolt Biotherapeutics (BOLT) CEO logs stock sales and an ESPP buy - Stock Titan

Sep 21, 2026

Sep 20, 2026

Bolt Biotherapeutics (BOLT) Climbs 6.43% to $3.56 as Shares Test Upper RangeMcClellan Oscillator - careplusvn.com

Sep 20, 2026

Sep 11, 2026

BOLT - Finviz

Sep 11, 2026

Sep 03, 2026

BOLT Q2 2026 Earnings: Wider-than-Expected Per-Share Loss of -$4.57 Highlights Cost PressuresEBITDA Margin Trends - vinanet.vn

Sep 03, 2026

Aug 31, 2026

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Barchart.com

Aug 31, 2026

BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Return On Assets - vinanet.vn

Aug 31, 2026

BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Earnings Deceleration Risk - careplusvn.com

Aug 31, 2026

BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Balance Sheet Strength - dars.gov.et

Aug 31, 2026

Aug 28, 2026

Bolt Biotherapeutics (BOLT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 28, 2026

Aug 19, 2026

Bolt (BOLT) Levels: Records a 2.60% Increase to $3.26 in the Current Update; Price Context: the Near-Term Reference Band Stretches From $3.10 to $3.42 in the Current UpdateTrend Following Picks - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Bolt (BOLT) Quarterly Figures: The EPS Result Is Below Expectation; Price Reaction: Shares Fall 0.72%Buyback Announcement Report - vinanet.vn

Aug 18, 2026

Aug 14, 2026

Bolt Biotherapeutics (BOLT) Gains 4.36% as Shares Test Key Technical LevelsLarge Cap Trends - Vinanet

Aug 14, 2026

Bolt Biotherapeutics (BOLT) Gains 4.36% as Shares Test Key Technical LevelsLarge Cap Trends - vinanet.vn

Aug 14, 2026

Aug 13, 2026

Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics - Stock Titan

Aug 13, 2026

Aug 11, 2026